Avalo Therapeutics (NASDAQ:AVTX) Given Neutral Rating at HC Wainwright

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a research report issued on Thursday,Benzinga reports.

AVTX has been the topic of several other reports. Piper Sandler began coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday. Finally, BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.33.

Avalo Therapeutics Stock Up 2.7 %

Shares of AVTX traded up $0.22 during mid-day trading on Thursday, hitting $8.21. 18,244 shares of the company traded hands, compared to its average volume of 76,732. Avalo Therapeutics has a 1 year low of $4.43 and a 1 year high of $34.46. The stock has a 50-day moving average price of $7.42 and a two-hundred day moving average price of $9.11.

Institutional Investors Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics in the 3rd quarter worth $9,186,000. Ikarian Capital LLC raised its holdings in Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after purchasing an additional 915,629 shares in the last quarter. Northern Trust Corp bought a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $168,000. Velan Capital Investment Management LP acquired a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $817,000. Finally, Tower Research Capital LLC TRC boosted its stake in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares in the last quarter. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.